MDMB-CHMICA

methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate

Aliases.MDMB-CHMINACA precursor name (incorrect)

Ultra-potent SCRA (sub-nanomolar EC50). Linked to more than 25 deaths in Europe 2014-2016.

Updated on 1 May 2026

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

Identifiers

Formula: C₂₃H₃₂N₂O₃
Molar mass: 384.51 g·mol⁻¹
CAS: 1971007-95-0
PubChem CID: 125181404
First described: 2014
Origin: Illicit market (academic origin unknown)
InChIKey: SRJKCVHWIDFUBO-HXUWFJFHSA-N

In plain terms

MDMB-CHMICA is an extremely potent synthetic cannabinoid - fractions of a milligram are enough to produce severe effects. Behind more than 25 deaths in Europe 2014-2016.

Receptors and activity

CB1
EC50 ≈ 0,26 nMAgonist
CB2
Agonist

Agonist
Partial agonist
Antagonist
Modulator
Inverse agonist

Hover over a row for the precise value (Ki, EC50…)

Subjective signature

Hover over an axis to read its definition.

Calm
25
Clarity
15
Sleep
60
Appetite
50
High
98

Editorial estimate, not clinical.

Pharmacology

MDMB-CHMICA is an indole-3-carboxamide (L-tert-leucinate methyl ester head; cyclohexylmethyl tail) characterised by Banister et al. (ACS Chem Neurosci 2016, PMID 27421060): CB1 EC50 = 0.26 nM (β-arrestin) - an ultra-potent full agonist. The EUDA risk assessment of 2016 documented ≥ 25 deaths in Europe (UK 18, Belgium, Hungary, Poland, Germany) between 2014-2016. Implementing Decision (EU) **2017/369** of 27 February 2017 (CELEX 32017D0369): mandatory control throughout the EU. France: **Decree of 31 March 2017** (NOR AFSP1710288A) - listed in annex IV of the decree of 22 February 1990.

Key sources.